Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera

The Key Chronic Hepatitis B Companies in the market include - Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Therapeutics, GSK, Drug Farm, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., Vir Biotechnology, Arbutus Biopharma, and others.
(Albany, New York) - September 11, 2026: DelveInsight's "Chronic Hepatitis B Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Chronic Hepatitis B, historical and forecasted epidemiology as well as the Chronic Hepatitis B market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Chronic Hepatitis B, offering comprehensive insights into the Chronic Hepatitis B revenue trends, prevalence, and treatment landscape. The report delves into key Chronic Hepatitis B statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Chronic Hepatitis B therapies. Additionally, we cover the landscape of Chronic Hepatitis B clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Chronic Hepatitis B treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Chronic Hepatitis B space.

To Know in detail about the Chronic Hepatitis B market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Hepatitis B Market Forecast [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]

Some of the key facts of the Chronic Hepatitis B Market Report:

*
The Chronic Hepatitis B market size in the 7MM was valued at approximately USD 1,603 million in 2025 and is projected to grow at a CAGR of 12.3% during the forecast period from 2025 to 2034 across the leading markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

*
In August 2026, GSK announced that its investigational treatment for chronic hepatitis B has received its first global regulatory approval in Japan. The company also reported that one of its key cancer therapies has been granted priority review by U.S. regulators for its potential use in treating rectal cancer.

*
In August 2026, AusperBio Therapeutics announced that the first patient has been dosed in a clinical study evaluating its investigational candidate, AHB-171. Developed to treat chronic Hepatitis B virus (HBV) infection, AHB-171 is an antisense oligonucleotide designed to significantly reduce hepatitis B surface antigens and suppress viral replication. Dosing the initial participant represents a major clinical milestone in AusperBio's mission to deliver a functional cure for patients suffering from chronic HBV worldwide.

*
In July 2026, Brii Biosciences Limited released topline end-of-treatment data from its Phase 2b ENRICH and ENHANCE studies evaluating BRII-179 for chronic hepatitis B virus (HBV) treatment. The ENRICH study demonstrated promising results, achieving hepatitis B surface antigen (HBsAg) loss rates of up to 42.9%, validating BRII-179's role in priming the immune system for functional cure strategies. Conversely, the ENHANCE triple-combination study did not show improved HBsAg loss rates over historical controls. The company will use these insights to select optimal combination regimens for future registrational trials.

*
In September 2025, Lion TCR, a clinical-stage biotechnology company, announced that it received Investigational New Drug (IND) clearance from the FDA to begin Phase 1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients with chronic hepatitis B (CHB). This approval marks the third major regulatory milestone for LioCyx-M004, which previously received Fast Track and Orphan Drug Designations for treating hepatitis B virus-related hepatocellular carcinoma (HBV-HCC).

*
Among the 7MM, the United States accounted for the highest market size in 2024, followed by Japan for Chronic Hepatitis B.

*
In the EU4 and the UK, Germany has the highest market size of approximately USD 65 million in 2024.

*
In 2024, the total market size for Chronic Hepatitis B in Japan was approximately 160 USD million.

*
During the forecast period (2024-2034), pipeline candidates such as Daplusiran/tomligisiran, Imdusiran (AB-729), and others are expected to drive the rise in Chronic Hepatitis B market size.

*
In 2024, the total prevalent cases of Chronic Hepatitis B was approximately 2,250,000 in the US.

*
In 2024, the total diagnosed cases of Chronic Hepatitis B was approximately 635,000 in the US.

*
In 2024, the age group-specific cases of CHB were approximately 10,000, 135,000, 160,000, 170,000, 125,000 and 31,000 cases for

*
In 2024, the compensated liver cases of CHB accounted 85% of all cases and decompensated liver cases of CHB accounted for 15% of the cases in the 7MM.

*
In 2024, the treated Cases of Chronic Hepatitis B was approximately 670,000 in the 7MM.

*
Key Chronic Hepatitis B Companies: Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Therapeutics, GSK, Drug Farm, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., Vir Biotechnology, Arbutus Biopharma, and others

*
Key Chronic Hepatitis B Therapies: VEMLIDY (tenofovir alafenamide), GSK3965193, PBGENE-HBV, SBT8230, GSK3965193, DF 006, AB 729, RG6346, RG7854, Bepirovirsen, Pradefovir, DA 2802, VIR-2218, AB-729, and others

*
The Chronic Hepatitis B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Hepatitis B pipeline products will significantly revolutionize the Chronic Hepatitis B market dynamics.

*
The United States recorded the highest prevalence of Chronic Hepatitis B, with an estimated 2 million cases reported in 2023.

*
In the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases, followed by Italy, while Spain had the lowest number of cases.

Chronic Hepatitis B Overview

Chronic Hepatitis B is a long-term infection of the liver caused by the hepatitis B virus (HBV). It occurs when the immune system cannot clear the virus after an acute infection, leading to persistent viral presence in the body for more than six months. This condition can cause inflammation and damage to the liver over time, increasing the risk of complications such as liver cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).

Get a Free sample for the Chronic Hepatitis B Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market [https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]

Chronic Hepatitis B Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Hepatitis B Epidemiology Segmentation:

The Chronic Hepatitis B market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalent Cases of Chronic Hepatitis B

*
Total Diagnosed Cases of Chronic Hepatitis B

*
Chronic Hepatitis B cases by Age group

*
Chronic Hepatitis B cases by Gender

*
Treated cases of Chronic Hepatitis B

*
Chronic Hepatitis B cases by impact on Liver

Download the report to understand which factors are driving Chronic Hepatitis B epidemiology trends @ Chronic Hepatitis B Epidemiology Forecast [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]

Chronic Hepatitis B Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Hepatitis B market or expected to get launched during the study period. The analysis covers Chronic Hepatitis B market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Hepatitis B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Hepatitis B Therapies and Key Companies

*
VEMLIDY (tenofovir alafenamide): Gilead Sciences

*
GSK3228836 (bepirovirsen): GlaxoSmithKline/Ionis Pharma

*
PBGENE-HBV: Precision Biosciences

*
SBT8230: Silverback Therapeutics

*
GSK3965193: GSK

*
DF 006: Drug Farm

*
AB 729: Arbutus bio

*
RG6346: Dicerna Pharmaceuticals

*
RG7854: Roche

*
Bepirovirsen: GSK

*
Pradefovir: Ligand Pharmaceuticals

*
Pradefovir: Ligand Pharmaceuticals

*
DA 2802: Dong-A ST Co.

*
VIR-2218: Vir Biotechnology

*
AB-729: Arbutus Biopharma

Discover more about therapies set to grab major Chronic Hepatitis B market share @ Chronic Hepatitis B Treatment Landscape [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]

Chronic Hepatitis B Market Drivers

*
High global disease burden: A large and persistent patient population, along with the risk of cirrhosis and hepatocellular carcinoma, continues to drive demand for effective chronic hepatitis B therapies.

*
Growing diagnosis and treatment initiatives: Expanded screening programs, simplified treatment guidelines, and improved access to HBV diagnostics are expected to increase the number of diagnosed and treated patients.

*
Strong unmet need for functional cures: Current therapies can effectively suppress viral replication but often require long-term treatment, creating demand for novel therapies with the potential to achieve a functional cure.

*
Robust pipeline development: Increasing research into novel antivirals, immunomodulators, RNA-based therapies, and combination approaches is expected to support market growth.

*
Government and global elimination initiatives: WHO's hepatitis elimination targets and efforts to expand testing, treatment, vaccination, and prevention are supporting greater investment in HBV management.

Chronic Hepatitis B Market Barriers

*
Low diagnosis and treatment rates: A significant proportion of people with chronic HBV infection remain undiagnosed or untreated, limiting the addressable treated population.

*
Lack of a definitive cure: Existing antiviral therapies primarily suppress HBV rather than completely eliminating the virus, and many patients require long-term or lifelong treatment.

*
High cost and access challenges: Limited access to specialists, diagnostic testing, monitoring, and innovative therapies can restrict treatment uptake, particularly in low- and middle-income countries.

*
Treatment adherence challenges: The long duration of therapy, concerns regarding side effects, and the need for continuous monitoring may negatively affect patient adherence.

*
Complex disease management: Variability in disease progression, treatment eligibility, and the need for long-term monitoring for liver complications can complicate patient management.

Scope of the Chronic Hepatitis B Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Chronic Hepatitis B Companies: Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Therapeutics, GSK, Drug Farm, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., Vir Biotechnology, Arbutus Biopharma, and others

*
Key Chronic Hepatitis B Therapies: VEMLIDY (tenofovir alafenamide), GSK3965193, PBGENE-HBV, SBT8230, GSK3965193, DF 006, AB 729, RG6346, RG7854, Bepirovirsen, Pradefovir, DA 2802, VIR-2218, AB-729, and others

*
Chronic Hepatitis B Therapeutic Assessment: Chronic Hepatitis B current marketed and Chronic Hepatitis B emerging therapies

*
Chronic Hepatitis B Market Dynamics: Chronic Hepatitis B market drivers and Chronic Hepatitis B market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Chronic Hepatitis B Unmet Needs, KOL's views, Analyst's views, Chronic Hepatitis B Market Access and Reimbursement

To know more about Chronic Hepatitis B companies working in the treatment market, visit @ Chronic Hepatitis B Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]

Table of Contents

1. Chronic Hepatitis B Market Report Introduction

2. Executive Summary for Chronic Hepatitis B

3. SWOT analysis of Chronic Hepatitis B

4. Chronic Hepatitis B Patient Share (%) Overview at a Glance

5. Chronic Hepatitis B Market Overview at a Glance

6. Chronic Hepatitis B Disease Background and Overview

7. Chronic Hepatitis B Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Hepatitis B

9. Chronic Hepatitis B Current Treatment and Medical Practices

10. Chronic Hepatitis B Unmet Needs

11. Chronic Hepatitis B Emerging Therapies

12. Chronic Hepatitis B Market Outlook

13. Country-Wise Chronic Hepatitis B Market Analysis (2020-2034)

14. Chronic Hepatitis B Market Access and Reimbursement of Therapies

15. Chronic Hepatitis B Market Drivers

16. Chronic Hepatitis B Market Barriers

17. Chronic Hepatitis B Appendix

18. Chronic Hepatitis B Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-hepatitis-b-market-statistics-expected-to-experience-major-growth-by-2034-according-to-delveinsight-gilead-sciences-glaxosmithkline-ionis-pharma-precision-biosciences-silverback-thera]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.